ConductScience.org, home
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Crohn's Disease
API referenceFor AI assistants

Trial · NCT03395184

Adverse events427

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 427

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
otherAnaemiaBlood and lymphatic system disordersInduction Period: Placebo QD079
otherAnaemiaBlood and lymphatic system disordersInduction Period: Ritlecitinib 200 mg/50 mg QD093
otherAnaemiaBlood and lymphatic system disordersInduction Period: Brepocitinib 60 mg QD072
otherAnaemiaBlood and lymphatic system disordersOLE Period: Placebo QD -> Ritlecitinib 50 mg QD336
otherAnaemiaBlood and lymphatic system disordersOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD084
otherAnaemiaBlood and lymphatic system disordersOLE Period: Placebo QD -> Brepocitinib 30 mg QD232
otherAnaemiaBlood and lymphatic system disordersOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD264
otherLymphopeniaBlood and lymphatic system disordersInduction Period: Placebo QD179
otherLymphopeniaBlood and lymphatic system disordersInduction Period: Ritlecitinib 200 mg/50 mg QD393
otherLymphopeniaBlood and lymphatic system disordersInduction Period: Brepocitinib 60 mg QD472
otherLymphopeniaBlood and lymphatic system disordersOLE Period: Placebo QD -> Ritlecitinib 50 mg QD036
otherLymphopeniaBlood and lymphatic system disordersOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD084
otherLymphopeniaBlood and lymphatic system disordersOLE Period: Placebo QD -> Brepocitinib 30 mg QD032
otherLymphopeniaBlood and lymphatic system disordersOLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD064
otherTinnitusEar and labyrinth disordersInduction Period: Placebo QD079
otherTinnitusEar and labyrinth disordersInduction Period: Ritlecitinib 200 mg/50 mg QD093
otherTinnitusEar and labyrinth disordersInduction Period: Brepocitinib 60 mg QD072
otherTinnitusEar and labyrinth disordersOLE Period: Placebo QD -> Ritlecitinib 50 mg QD336
otherTinnitusEar and labyrinth disordersOLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD184
otherTinnitusEar and labyrinth disordersOLE Period: Placebo QD -> Brepocitinib 30 mg QD032

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03395184/events

API referenceFor AI assistants